tradingkey.logo
搜索

Biomerica Inc

BMRA
添加自选
2.340USD
-0.090-3.70%
收盘 05/15, 16:00美东报价延迟15分钟
7.23M总市值
亏损市盈率 TTM

Biomerica Inc

2.340
-0.090-3.70%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-3.70%

5天

+5.41%

1月

+6.36%

6月

-2.90%

今年开始到现在

-7.14%

1年

-35.71%

TradingKey Biomerica Inc股票评分

单位: USD 更新时间: 2026-05-15

操作建议

Biomerica Inc当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名148/206位。机构持股占比非常高,中期看,股价处于平稳状态。近一个月,市场表现较强,基本面评分较高,但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Biomerica Inc评分

相关信息

行业排名
148 / 206
全市场排名
412 / 4482
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Biomerica Inc亮点

亮点风险
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
业绩增长期
公司处于发展阶段,最新年度总收入5.31M美元
估值合理
公司最新PE估值-1.45,处于3年历史合理位
机构减仓
最新机构持股94.38K股,环比减少72.64%
Wasatch 全球投资公司持仓
明星投资者Wasatch 全球投资公司持仓,最新持仓市值0.00

分析师目标

根据 0 位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Biomerica Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Biomerica Inc简介

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
公司代码BMRA
公司Biomerica Inc
CEOIrani (Zackary S)
网址https://biomerica.com/
KeyAI